Alcon Revenue 2019-2022 | ALC

Alcon annual/quarterly revenue history and growth rate from 2019 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Alcon revenue for the quarter ending September 30, 2022 was $2.140B, a 1.81% increase year-over-year.
  • Alcon revenue for the twelve months ending September 30, 2022 was $8.695B, a 7.58% increase year-over-year.
  • Alcon annual revenue for 2021 was $8.291B, a 21.34% increase from 2020.
  • Alcon annual revenue for 2020 was $6.833B, a 8.99% decline from 2019.
  • Alcon annual revenue for 2019 was $7.508B, a 4.96% increase from 2018.
Alcon Annual Revenue
(Millions of US $)
2021 $8,291
2020 $6,833
2019 $7,508
2018 $7,153
Alcon Quarterly Revenue
(Millions of US $)
2022-09-30 $2,140
2022-06-30 $2,217
2022-03-31 $2,189
2021-12-31 $2,149
2021-09-30 $2,102
2021-06-30 $2,110
2021-03-31 $1,930
2020-12-31 $1,940
2020-09-30 $1,838
2020-06-30 $1,214
2020-03-31 $1,841
2019-12-31 $1,913
2019-09-30 $1,868
2019-06-30 $1,903
2019-03-31 $1,824
2018-12-31
2018-09-30 $1,762
2018-06-30 $1,820
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $33.321B $8.291B
Alcon Inc. researches, develops, manufactures, distributes, and sells a full suite of eye care products. Alcon operates within two segments, Surgical and Vision Care. The Surgical segment is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery, and includes implantables, consumables, and surgical equipment required for these procedures. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, and a comprehensive portfolio of ocular health products, including products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $214.645B 22.45
Edwards Lifesciences (EW) United States $46.932B 32.30
STERIS (STE) Ireland $18.019B 22.42
Teleflex (TFX) United States $10.587B 17.18
Fresenius Medical Care AG KGaA (FMS) Germany $8.996B 9.03
Penumbra (PEN) United States $7.452B 1783.82
Globus Medical (GMED) United States $7.103B 36.11
Integer Holdings (ITGR) United States $2.367B 19.00
Glaukos (GKOS) United States $2.263B 0.00
Nevro (NVRO) United States $1.556B 0.00
Paragon 28 (FNA) United States $1.534B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.246B 17.74
Artivion (AORT) United States $0.520B 0.00